Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease
出版年份 2021 全文链接
标题
Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease
作者
关键词
-
出版物
FASEB JOURNAL
Volume 35, Issue 10, Pages -
出版商
Wiley
发表日期
2021-09-06
DOI
10.1096/fj.202100774r
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling
- (2020) J. L. Woodhead et al. PHARMACEUTICAL RESEARCH
- Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling
- (2020) Caroline R. Sussman et al. CELLULAR SIGNALLING
- Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2–Dependent Mechanism in Polycystic Kidney Disease
- (2020) Nidhi Dwivedi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease
- (2019) Jacob A. Torres et al. JOURNAL OF CLINICAL INVESTIGATION
- Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
- (2019) Annarita Di Mise et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ADPKD current management and ongoing trials
- (2019) Francesca Testa et al. JOURNAL OF NEPHROLOGY
- CaSR signaling down-regulates AQP2 expression via a novel microRNA pathway in pendrin and NaCl cotransporter knockout mice
- (2018) Marianna Ranieri et al. FASEB JOURNAL
- Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells
- (2018) Annarita Di Mise et al. Scientific Reports
- A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
- (2018) Fouad T. Chebib et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis
- (2018) Giuseppe Vezzoli et al. Urolithiasis
- External Ca 2+ regulates polycystin-2 (TRPP2) cation currents in LLC-PK1 renal epithelial cells
- (2017) Xiao Qing Dai et al. EXPERIMENTAL CELL RESEARCH
- Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
- (2017) Vicente E Torres et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
- (2017) Vicente E. Torres et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016
- (2016) Fouad T. Chebib et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Localization and function of the renal calcium-sensing receptor
- (2016) Daniela Riccardi et al. Nature Reviews Nephrology
- Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors
- (2016) Jeffrey L. Woodhead et al. TOXICOLOGICAL SCIENCES
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
- (2015) Paul B. Watkins et al. DRUG SAFETY
- Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model
- (2014) K. Hopp et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry
- (2014) E. M. Spithoven et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase
- (2013) Nutthapoom Pathomthongtaweechai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy
- (2013) Isaline Rowe et al. NATURE MEDICINE
- Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
- (2012) Katharina Hopp et al. JOURNAL OF CLINICAL INVESTIGATION
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
- (2012) Vicente E. Torres et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcimimetics inhibit renal pathology in rodent nephronophthisis
- (2011) Neal X. Chen et al. KIDNEY INTERNATIONAL
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
- (2011) V. Takiar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD
- (2009) V. H. Gattone et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease
- (2008) X. Wang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Autosomal Dominant Polycystic Kidney Disease
- (2008) Jared J. Grantham NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started